Carcinoid syndrome historical perspective: Difference between revisions
No edit summary |
|||
| Line 14: | Line 14: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
==References== | |||
{{Reflist|2}} | |||
{{WS}} | |||
{{WH}} | |||
[[Category: | [[Category:Gastroenterology]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category: | [[Category:Pulmonology]] | ||
[[Category:Hematology]] | |||
Revision as of 19:51, 15 July 2016
|
Carcinoid syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Carcinoid syndrome historical perspective On the Web |
|
American Roentgen Ray Society Images of Carcinoid syndrome historical perspective |
|
Risk calculators and risk factors for Carcinoid syndrome historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Carcinoid syndrome was first described by Siegfried Oberndorfer, a German pathologist in 1907. Endocrine related properties of carcinoid syndrome was described by Gosset and Masson in 1914.[1]
Historical Perspective
Carcinoid syndrome was first described in 1907 by Siegfried Oberndorfer, a German pathologist at the University of Munich, who coined the term karzinoide, or "carcinoma-like", to describe the unique feature of behaving like a benign tumor despite having a malignant appearance microscopically. The recognition of their endocrine-related properties were later described by Gosset and Masson in 1914, and these tumors are now known to arise from the enterochromaffin (EC) and enterochromaffin-like (ECL) cells of the gut.[1]